Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
出版年份 2020 全文链接
标题
Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
作者
关键词
-
出版物
JOURNAL OF CLINICAL PATHOLOGY
Volume -, Issue -, Pages jclinpath-2020-206466
出版商
BMJ
发表日期
2020-06-27
DOI
10.1136/jclinpath-2020-206466
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Disease
- Immunotherapy of melanoma: facts and hopes
- (2019) Sarah A Weiss et al. CLINICAL CANCER RESEARCH
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer
- (2018) Daichi Fujimoto et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- (2018) Shona Hendry et al. Journal of Thoracic Oncology
- Tumor biomarker testing in non-small-cell lung cancer: A decade of change
- (2018) Paul A. VanderLaan et al. LUNG CANCER
- Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
- (2018) Markus Eckstein et al. EUROPEAN JOURNAL OF CANCER
- A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
- (2018) Cory Batenchuk et al. JOURNAL OF CLINICAL PATHOLOGY
- Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
- (2018) Vamsidhar Velcheti et al. PLoS One
- Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
- (2017) Andreas H Scheel et al. HISTOPATHOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
- (2017) Maria Tretiakova et al. MODERN PATHOLOGY
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- (2017) Katerina Ancevski Hunter et al. Molecular Diagnosis & Therapy
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The landscape of metastatic progression patterns across major human cancers
- (2015) Jan Budczies et al. Oncotarget
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now